Smoothsailing
Regular
We can only hope that one of Sean important meetings was with Apples AI main man Mr John Giannandrea....This would be insane.
Imagine
We can only hope that one of Sean important meetings was with Apples AI main man Mr John Giannandrea....This would be insane.
Let's hope MF keeps all their BRN posts in a burn box.
Yes, I do believe that Mickelpenis is going to have some serious egg on his face at some point in the not too distant futureLet's hope MF keeps all their BRN posts in a burn box.
Perhaps they could explain TeNNs to their readers.
Sounds like the professor, is impressed enough to become a shareholder in our Company.Not sure if this was shared. Two lectures from different universities talking about Akida.
Miss the copy of the link.
View attachment 64584
Learning
Great read FMF.
Oh wow, if this ends up being the Brainchip train, then buckle up because this could become one hell of a ride!
Video below does work just click watch on YouTubeNice to see Tata Elxsi still on the neuromorphic train.
Multimodal AI and Neuromorphic AI: Detection, Diagnosis, Prognosis - Tata Elxsi
Discover how Multimodal and Neuromorphic AI lead healthcare from reactive to proactive. This article delves into Responsible AI and its transformative impact.ai.tataelxsi.com
MULTIMODAL AI AND NEUROMORPHIC AI: DETECTION, DIAGNOSIS, PROGNOSIS
Navigate
The synergy of cutting-edge technologies like Multimodal and Neuromorphic AI signals a pivotal shift from reactive to proactive healthcare. This article explores captivating use cases, offering insights on the implementation of Responsible AI.
Join us as we navigate the frontier of healthcare, where the synergy of innovation and responsibility promises a revolution in patient care and well-being.
Current state of AI adoption in Healthcare
Unlocking the full potential of AI in healthcare is an uncharted journey. From optimising drug combinations to spearheading clinical correlation and toxicity studies, AI is set to redefine every facet of the industry. Despite its transformative capabilities, AI remains a niche technology, requiring a nuanced understanding of its application in healthcare.
The tides are changing as the healthcare sector recognises the urgency for an interdisciplinary approach, marrying engineering with medical science. This paradigm shift signals an imminent era where AI’s vast capabilities will revolutionise diagnostics, patient treatment, protocols, drug development and delivery, and prescription practices over the next decade.
Join us as we navigate the frontier of healthcare, where the synergy of innovation and responsibility promises a revolution in patient care and well-being.
Multimodal AI and Neuromorphic Technology – A new era in Preventive Healthcare
In the ever-evolving landscape of healthcare, the amalgamation of Multimodal AI and Neuromorphic Technology marks a pivotal moment—a shift from reactive medicine to a proactive, preventive healthcare paradigm. This synergy is not just a collaboration of cutting-edge technologies; it’s a gateway to a future where wellness takes centre stage.
These technologies hold promise to transform healthcare by enhancing diagnostics, enabling personalised medicine, predicting long-term prognosis and contributing to innovations in therapeutic interventions.
Let’s delve into compelling use cases and glimpse the future of preventive healthcare.
The tides are changing as the healthcare sector recognises the urgency for an interdisciplinary approach, marrying engineering with medical science. This paradigm shift signals an imminent era where AI’s vast capabilities will revolutionise diagnostics, patient treatment, protocols, drug development and delivery, and prescription practices over the next decade.
Join us as we navigate the frontier of healthcare, where the synergy of innovation and responsibility promises a revolution in patient care and well-being.
Defining Multimodal and Neuromorphic AI
Multi-modal AI
Multimodal AI refers to the artificial intelligence systems that process and analyse data from multiple modalities or sources. In healthcare, these modalities often include both visual and clinical data. Visual data may include medical images from scans, while clinical data encompasses patient records, parameters, and test reports. Multimodal AI integrates these diverse data types to provide a comprehensive understanding, draw meaningful insights and give suggestions based on data and image analytics.
Neuromorphic Technology
The term “neuromorphic” comes from the combination of “neuro” (related to the nervous system) and “morphic” (related to form or structure). Neuromorphic technology is an innovative approach in computing that draws inspiration from the structure and function of a human brain. These are AI powered by brain-like computing architectures. It can help process larger amount of data with less computing power, memory and electric power consumption. Neuromorphic Technology utilises Artificial Neural Networks (ANN) and Spiking Neural Networks (SNN) to mimic the parallel processing, event-driven nature, and adaptability observed in biological brains.
Multimodal Inputs
- Medical Images
- Lab Reports
- Clinical History
- Patient Demographic Information
Fusion Module
Cross-modal attention mechanism to dynamically weigh the importance of text, video, and other parameters for calculating index to decide priority of selection.
Inference Outputs
Inference Results for
- Diagnostic
- Prognostic
- Lifestyle Recommendation
- Disease Prediction
Use Cases of Multimodal and Neuromorphic AI
Early Screening & Disease Detection
Multimodal AI
- Integrates visual and clinical data for holistic analysis.
- Advanced –image recognition for early detection.
- Comprehensive patient profiling.
Neuromorphic Technology
- Efficient pattern recognition for subtle disease indicators.
- Event-driven processing for real-time detection. This is crucial for detecting anomalies or irregularities that may be early signs of diseases.
- Continuous monitoring for dynamic changes. This continuous surveillance is especially valuable for conditions with varying symptoms.
Diagnosis
Multimodal AI
- Integrated diagnostic insights from diverse data.
- Cross-verification for reliability.
- Tailored treatment plans based on nuanced understanding.
- Continuous updates based on latest findings reported in the subject.
Neuromorphic Technology
- Large and Efficient data processing with minimal energy consumption. This efficiency contributes to faster and more accurate diagnoses.
- Allows integration of more complex algorithms on wearable devices; makes diagnostics more real-time and helps timely interventions
- Implantable devices can be made AI enabled with Neuromorphic computing, due to the low computing requirement and power consumption, making the diagnosis and management more precise and real-time.
- Adaptive intelligence for dynamic adjustments. This adaptability enhances the precision of diagnostic processes. This event-driven processing aligns with the dynamic nature of healthcare data allowing for more accurate and timely diagnoses.
- SNN for real-time response
and accuracy.Prognosis
Multimodal AI
- Research Advancements: Facilitates discovery of new insights, contributing to medical advancements and innovations.
- Personalised Prognostic Models: Considering both visual and clinical data, these models account for individual variations, and correlate with prior case records and provide more accurate predictions of disease outcomes.
- Dynamic Adaptability: The adaptability of multimodal AI to changing data patterns ensures that prognostic models can dynamically adjust based on evolving patient conditions and improve prognosis predictions
Neuromorphic Technology
- Analysis of longitudinal data for predicting disease progression.
- Dynamic adaptability in prognostic models that can adjust to changing data patterns. This adaptability improves prognosis prediction accuracy for evolving patient conditions.
- Personalised prognostic insights based on individual variations can help in more accurate predictions tailored to individual patient profiles.
Tata Elxsi Use Case
Disease Detection and Diagnosis
Utilising Neuromorphic Technology, we’ve achieved significant advancements in the analysis of medical images on low-computing embedded platforms, enabling on-field diagnostics of ultrasound images.
This innovative approach provides critical diagnostic information for musculoskeletal injuries, including tissue damage extent, recovery progress, and healing time predictions, all with enhanced efficiency and device portability making it ideal for applications such as sports medicine.
Applications of Multimodal and Neuromorphic AI
Multimodal AI
- Comprehensive Patient Analysis
- Diagnostic Accuracy
- Mental Health and Behavioural Analysis
- Lifestyle Reviews and Recommendations
- Management of Chronic Diseases like Diabetes/HT/Cardiac Diseases with continous monitoring and personalised medications
- Diagnosis/Management and Prognosis of various types of cancers, Digital Drug Trials, Effective Pandemic Surveillance and staging, Gene Therapy and Genomics
- Recommendations for interventions and Prioritisation of therapeutic resources and modalities
Neuromorphic Technology
- Implants, Wearables Devices
- Processing Large Data
- Medical Imaging Analysis
- Drug Discovery and Personalised Medicine
- Robotic Surgery Assistance
- Neurological Disorder Understanding
- Patient Care and Rehabilitation
- Predictive Analytics for Healthcare Management
- Energy Efficient Remote Monitoring
The Synergy of MLOps and Advanced AI
The transformative impact of MLOps across operational efficiency, data management, patient outcomes, and the overall quality of care is unmistakable. In the quest for advancing healthcare, the convergence of Machine Learning Operations (MLOps) with Multimodal and Neuromorphic AI has emerged as a game-changer. These technologies can help in seamless deployment, continuous monitoring, and collaborative development across various stakeholders in the healthcare ecosystem.
While Advanced AI Technologies offer the potential for improvising the use cases, the application of MLOps can be instrumental in strengthening and regulating these advancements. It achieves this by bringing in streamlined AI development processes, dataset management, continuous monitoring of model accuracy across different versions, ensuring the deployment of thoroughly vetted versions for clinical use.
Additonally, MLOps frameworks enable and learn from deviations, further enhancing their efficacy in healthcare applications.
Use Cases
Disease Detection
Disease Prediction and Prevention
Real World Application – Early Detection of Chronic Disease, Infectious Disease Monitoring
Healthcare Fraud Detection
Real World Application – Claims Analysis, Identify Theft Prevention
Medical Imaging Analysis
Real World Application – Early Cancer Detection, Neurological Disorders Diagnosis
Genomic Research
Real World Application – Cancer Genomics, Rare Genetic Diseases
Diagnosis
Drug Discovery and Development
Real World Application – Protein Folding Prediction, Drug Toxicity Prediction
Personalised Medicine
Real World Application – Oncology and Targeted Therapies, Chronic Disease Management
Healthcare Resource Management
Real World Application – Emergency Room Digitalised Management, Pharmaceutical Supply Chain Management
Prognosis
Prediction of Clinical Outcome
Real World Application – Prediction of recovery time and quality of life, Adverse Effects, Short term and long term impact
Remote Patient Monitoring
Real World Application – Chronic Disease Management, Post Surgery Monitoring
Responsible AI – Navigating Ethical Frontiers
In the realm of AI, addressing bias stands as a pivotal ethical imperative, particularly in fields like medical analysis where the demand for precision is ethically, legally, and morally paramount. As AI practitioners, our commitment to responsible AI requires rigorous testing using diverse, unbiased anonymised datasets, continual monitoring to mitigate biases, and a steadfast dedication to achieving fair outcomes across diverse patient populations.
Moreover, the ethical considerations extend to the strategic utilisation of data. The foundation of responsible AI in healthcare is laid upon a robust ethical framework that guides the entire lifecycle of Neuromorphic and Multimodal AI systems. Stakeholders must unwaveringly adhere to established ethical principles, ensuring transparency, fairness, and accountability at every stage of AI implementation.
When we delve into the realm of Gen AI, the potential for malpractice looms. Consider scenarios where a patient, with normal renal function manageable through medication, undergoes a renal scan. Unscrupulous use of Gen AI could manipulate images, creating false lesions, leading to unnecessary surgeries or even nephrectomy which can benefit illegal organ trade
Thus, the imperative lies in defining strong ethical boundaries, implementing robust audits, and establishing legal frameworks to prevent data manipulation and ensure the highest standards of integrity.
In embracing these technological advancements responsibly, we are not just witnessing the future of healthcare; we are actively shaping it. The era of proactive, preventive healthcare beckons, promising a future where wellness is at the forefront of the industry’s evolution.
The shift from traditional, one-size-fits-all medical practices, prone to misinterpretation and diagnostic errors, to AI-enhanced methodologies, heralds a new era of precision and personalised care. AI’s capability to analyse a broad spectrum of patient data—ranging from genetic backgrounds to lifestyle factors—promises a departure from misdiagnoses and introduces tailored therapeutic interventions.
AI and multimodal technologies enable a holistic view of the patient’s health, integrating diverse data points. While, Neuromorphic computing advances the portability of medical devices, including wearables and implants, transforming them into intelligent systems capable of adapting to varying conditions.
As thought leaders in the healthcare industry, our commitment to responsibly integrate these technologies paves the way for a future where healthcare is not only reactive, but anticipatory, personalised, and universally accessible.
Author
Anup S S
Practice Head, Artificial Intelligence, Tata Elxsi
Anup S.S. is a visionary in leveraging Artificial Intelligence, Machine Learning and Deep Learning. Leading breakthrough AI projects in healthcare, Anup’s strategic insight and innovation ignite client success, unlocking AI’s full potential.
Book Your Exclusive Print Copy Now!
© 2024 TATA ELXSI
PRIVACY POLICY
COOKIE POLICY
TERMS OF USE
Facebook Twitter Youtube Linkedin Instagram Envelope
Hi @Terroni2105A very exciting company to watch: Alat
It is Saudi Arabia's ambition to build a world-class manufacturing hub in the Kingdom through next-generation technologies and sustainable practices.
Alat, headquartered in Riyadh, has been established to create a global champion in electronics and advanced industrial segments and mandated to create world class manufacturing enabled by global innovation and technology leadership. Alat is partnering with global technology leaders to transform industries like semiconductors, smart devices and next-gen infrastructure while establishing world class businesses in the Kingdom, powered by clean energy.
They have received $100 Billion USD in funding from the Saudi Arabia Public Investment Fund (PIF).
Alat is led by His Royal Highness Crown Prince Mohammed bin Salman bin Abdulaziz Al-Saud who is the Crown Prince and Prime Minister of the Kingdom of Saudi Arabia
On the Alat Executive Leadership team is Ross Jatou, President of their Semiconductors Business unit. He only formally announced his appointment yesterday.
Ross came from Onsemi where he was for 8 years and the Senior Vice President and General Manager of their Intelligent Sensing Group. He was with Nvidia for 14 years prior to Onsemi.
Ross is well aware of BrainChip where he re-posted this on LinkedIn 3 weeks ago.
View attachment 57834
Watch the Alat CEO video here https://www.alat.com/en/about/what-is-alat/
Alat has partnered for a joint venture with Softbank Alat and SoftBank Group form a strategic partnership to manufacture groundbreaking industrial robots in the Kingdom | SoftBank Group Corp.
“The new JV will build industrial robots based on intellectual property developed by SoftBank Group and its affiliates that will perform tasks with minimal additional programming, that are ideally suited for industrial assembly and applications in manufacturing and production. The robot manufacturing factory that the JV will create in the Kingdom is a lighthouse factory, that will use the latest technology to manufacture unprecedented next generation robots to perform a wide variety of tasks”. The first factory is targeted to open in December 2024.
This is what Alex Divinsky (Ticker Symbol You) posted about Alat earlier today.
View attachment 57835
https://www.linkedin.com/posts/acti...qv?utm_source=share&utm_medium=member_desktop
Chippers, it would be massive if we got in with Alat !
And I’ve got positive vibes about it.
DYOR.
So why isn't Sean booking the first premium economy ticket to see if they want to invest?Hi @Terroni2105
I just saw the below and the previous LinkedIn post by Ross on their TOF being used in our demo with Onsemi.
Did a search and saw you already picked up on them.
Agree, would be a nice hook up and I like who he is also speaking with. Would like BRN to have a seat at that table for sure
Ross Jatou
President - Semiconductors at ALAT
1mo
It was an honor to meet with Cristiano Amon, the CEO of Qualcomm, during his visit to Riyadh. Our discussions centered around exploring potential collaboration opportunities between Qualcomm and Alat. It was an insightful conversation, and we hope to continue our dialogue in the future. Thank you for taking the time to meet with us.
Hi Dingo,Sounds like the professor, is impressed enough to become a shareholder in our Company.
We can't know how big his "bet" is though.
And anyway, what would he know?
He's probably just caught up in the "hype" like the rest of us ..
"The automotive electronics development cycle is considerably longer than that of complex consumer electronics like smartphones, often compared to dog years."View attachment 64605
On May 9, 2024, the U.S. National Highway Transportation Safety Administration (NHTSA) issued a final rule mandating that all passenger vehicles and light trucks sold in the United States after September 2029 must be equipped with an Automated Emergency Braking System (AEB). This is a significant step forward in mainstreaming technology that is already standard in all new luxury vehicles and available as an enhanced safety upgrade in most mass-market models. However, while the NHTSA's decision is welcome for driver, pedestrian, and cyclist safety, the effectiveness of these systems, particularly in night driving conditions, remains a concern due to the limitations of cost-efficient sensors used in mass-market vehicles.
The automotive electronics development cycle is considerably longer than that of complex consumer electronics like smartphones, often compared to dog years. The NHTSA 2029 mandate is expected to trigger a push among automotive OEMs to meet the new requirements economically within the next five years. AEB technology, first introduced by Volvo in 2010, has proven effective enough over time to become pervasive. The most advanced AEB systems combine a variety of sensors and sensor types (radar, camera, lidar, ultrasonic) and the silicon processing power to enhance accuracy and reduce false positives, which can potentially cause collisions that the systems are designed to prevent. However, last month’s mandate is bound to have an impact on some OEMs, forcing them to balance accuracy, BOM cost, and system complexity for mass market vehicles.
A critical issue for AEB systems is their performance in low-light conditions. Research supports the need for improved nighttime AEB performance. According to Jessica Cicchino's study in Accident Analysis & Prevention (AAP), "AEB with pedestrian detection was associated with significant reductions of 25%-27% in pedestrian crash risk and 29%-30% in pedestrian injury crash risk. However, there was no evidence that the system was effective in dark conditions without street lighting…"【Jessica Cicchino, AAP May 2022】
The effectiveness of automotive CMOS image sensors commonly used in these systems diminishes after dark. This is particularly concerning since drivers with limited visibility and reaction time are most dependent on AEB systems and other ADAS systems at night. Pedestrian fatalities in the U.S. have nearly doubled since 2001, with over 7,500 deaths nationwide in 2021, and about 77% of pedestrian fatalities happening after dark. Although the NHTSA's ruling is a positive move towards improving safety, the challenge of cost-effective solutions for nighttime driving remains for nearly 80% of the vehicle-on-pedestrian fatalities the mandate certainly seeks to mitigate.
Fortunately, AI-based computational imaging offers a promising solution. By applying real-time denoising using neural networks and embedded neural network processors (NPUs), the nighttime range and accuracy of automotive sensors can be significantly enhanced. This AI denoising software runs on existing automotive SoCs with embedded NPUs and removes temporal and spatial noise from the RAW image feed from the sensor before processing, allowing the analog gain and exposure time to be increased without increasing the associated sensor noise.
This method does not require any modifications or recalibration of the existing image signal pipeline (ISP). In initial OEM road tests, AI denoising works effectively with both high-cost low-light-capable sensors and mainstream automotive CMOS sensors, effectively giving them "steroids" for better and more accurate night vision. This improved night vision translates into earlier and more accurate computer vision results such as nighttime pedestrian detection in AEB systems.
Since this is a software upgrade to existing and planned ECUs leveraging existing/roadmap Tier-2 fabless SoCs, the time required for integration, testing, and productization is much lower compared to hardware-based alternatives.
I am proud to be part of a dynamic team of AI computational image scientists and software engineers who are changing the world by delivering technology that will potentially mitigate thousands of fatalities in the coming years.
For more information on how AI-based computational imaging can improve the nighttime performance and accuracy of ADAS, as well as human vision-assist systems, contact me via LinkedIn or consult one of our Tier-2 fabless partners about their adoption plans for AI-based computational imaging from Visionary.ai.
Surely if they are, it has to be soon during the ai boom that is currently underway everywhere.Will they ever sign anyone ??